New data confirms VivAer provides consistent and long-lasting symptom relief for patients suffering from nasal airway obstruction (NAO) due to nasal valve collapse (NVC).


RT’s Three Key Takeaways:

  1. Long-Term Efficacy: The AERWAY study shows that VivAer delivers sustained symptom relief from nasal airway obstruction due to nasal valve collapse, with over 83% of patients maintaining improvement at three years post-procedure.
  2. Strong Safety Profile: No serious device- or procedure-related side effects were reported over the three-year follow-up, and only 3.2% of patients required additional nasal valve procedures.
  3. Minimally Invasive Solution: VivAer provides a durable, non-surgical treatment option for nasal obstruction using temperature-controlled radiofrequency, allowing patients to recover quickly with minimal downtime.


Aerin Medical Inc announced the publication of positive three-year outcomes from the AERWAY clinical study that underscore the durability of the VivAer procedure. The prospective, single-arm, multicenter clinical study, published in OTO Open, confirms that VivAer provides consistent and long-lasting symptom relief for patients suffering from nasal airway obstruction (NAO) due to nasal valve collapse (NVC).

AERWAY was conducted at 12 sites across the US to evaluate the long-term efficacy and safety of temperature-controlled radiofrequency (TCRF) treatment with VivAer. At three years post-procedure, patients demonstrated sustained symptom relief, meaningful reductions in medication use, and no serious device- or procedure-related side effects. These improvements in symptom burden at three years are consistent with outcomes reported at previously assessed intervals of 3, 6, 12, and 24 months.

Key Study Findings:

  • Sustained Symptom Relief: 83.3% of patients were responders, with mean NOSE scores improving by 52.6%
  • Low Nasal Valve Reintervention Rate: 3.2% of patients required additional procedures targeting the nasal valve at 3 years
  • Excellent Safety Profile: No device- or procedure-related serious side effects reported over the 3-year follow-up

“These long-term results reinforce VivAer’s potential as a safe and effective long-term solution for patients experiencing nasal airway obstruction,” said William C. Yao, MD, Associate Professor at McGovern Medical School at UTHealth Houston and principal investigator of the AERWAY study. “Providing sustained symptom relief through a durable, minimally invasive alternative to traditional surgery may elevate the standard of care available to our patients.”

“Combined with the recently published VATRAC study, these findings further validate VivAer as a consistently effective solution supported by high quality evidence,” said Scott Wolf, Founder and Chief Medical Officer of Aerin Medical. “With 20 peer-reviewed publications to date, the growing body of evidence continues to build confidence among physicians treating nasal valve dysfunction.”